Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-031911
Filing Date
2021-08-06
Accepted
2021-08-06 16:05:24
Documents
1
Period of Report
2021-08-04

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4156
  Complete submission text file 0000899243-21-031911.txt   5558
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Issuer) CIK: 0001651431 (see all company filings)

EIN.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address
Wooldridge James (Reporting) CIK: 0001710641 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39425 | Film No.: 211152893